EnClear Therapies, a Cambridge, Mass.-based life sciences company developing device-based therapies for the treatment of neurodegenerative disease, raised $10m in Series A financing.

The round was led by 20/20 HealthCare Partners with participation from Peter Thiel, Amgen Ventures, GHS Fund (Quark Venture LP and GF Securities), Christian Angermayer’s Presight Capital and Dolby Ventures.

Led by Anthony DePasqua, Chief Executive Officer and Co-founder, EnClear Therapies is a life sciences company developing a device-based therapy to aid in the treatment of neurodegenerative disease and delivery and monitoring of cerebrospinal fluid (CSF).

The company’s proprietary therapeutic platform focuses on removing toxic proteins from the CSF.

The company’s first products will target improving the lives of patients with Amyotrophic Lateral Sclerosis (ALS) and Progressive Supranuclear Palsy (PSP). | To read full story, visit https://startuparound.com/read/1582147810.2487123/EnClear-Therapies-Raises-$10M-in-Series-A-Financing?ref=audio_experience